Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)
Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML). ASH 2015. Poster
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo. ASH 2015. Poster
CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value
CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value. ASH 2015. Poster
A Novel Agent SL-401 Triggers Anti-Myeloma Activity by Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism
A Novel Agent SL-401 Triggers Anti-Myeloma Activity by Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-associated Mechanism. ASH 2015. Poster
SL-401 Activity Against AML Blasts and Its Correlation With CD123 Levels
SL-401 Activity Against AML Blasts and Its Correlation With CD123 Levels. AACR 2015. Poster
SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis
SL-401, A Novel Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-triggered Myeloma Cell Growth and Prevents Osteoclastogenesis. ASH 2014. Poster
Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms
Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms. ASH 2014. Abstract
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia. ASH 2014. Abstract
Effect of a Novel Agent SL-401, Targeting Interleukin-3 Receptor (IL-3R) on Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Osteolytic Bone Disease
Effect Of A Novel Agent SL-401, Targeting Interleukin-3 Receptor (IL-3R) On Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth And Osteolytic Bone Disease. ASCO 2014. Abstract | Poster
An Update on the Robust Clinical Activity of SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH 2013. Abstract | Poster